References
  1. Alton I. Iron Deficiency Anemia. In: Strang J, Story M, eds. Guidelines for Adolescent Nutrition Services. Minneapolis, MN: Center for Leadership, Education and Training in Maternal and Child Nutrition, Division of Epidemiology and Community Health, School of Public Health, University of Minnesota; 2005:101-108.
  2. Ekman M, Reizenstein P. Comparative absorption of ferrous and heme-iron with meals in normal and iron deficient subjects. Z Ernährungswiss. 1993;32:67-70
  3. Seligman PA, Moore GM, Schleicher RB. Clinical studies of HIP: An oral heme-iron product. Nutr Res. 2000;20(9):1279-1286.
  4. Frykman E, Bystrom M, Jansson U, Edberg A, Hansen T. Side effects of iron supplements in blood donors: superior tolerance of heme iron. J Lab Clin Med. 1994;123:561-564.
  5. Office of Dietary Supplements. Dietary Supplement Fact Sheet: Folate. National Institutes of Health. 4/15/2009; Available at: http://dietary-supplements.info.nih.gov/factsheets/folate_pf.asp. Accessed 3/18/2010.
  6. Office of Dietary Supplements. Dietary Supplement Fact Sheet: Vitamin B12. National Institutes of Health. 10/12/2009; Available at: http://dietary-supplements.info.nih.gov/factsheets/vitaminb12_pf.asp. Accessed 3/18/2010.
  7. Anemia Monograph: General Overview. National Anemia Action Council. 5/29/2008; Available at: www.anemia.org/professionals/monograph Accessed 2/1/2010.
  8. Hallberg L. Bioavailability of dietary iron in man. Annu Rev Nutr. 1981;1:123-147.
  9. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104 Suppl 2:S5-S9.
  10. A Physician’s Guide to Oral Iron Supplements, National Anemia Action Council. 11/6/2008; Available at www.anemia.org/professionals/feature-articles/content.php?contentid=306§ionid=15 Accessed 2/1/2010.
  11. Nissenson AR, Berns JS, Sakiewicz P, et al. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis. 2003;42(2):325-330.
  12. Wilson A, Reyes E, Ofman J. Prevalence and Outcomes of Anemia in Inflammatory Bowel Disease: A Systematic Review of Literature. The American Journal of Medicine. 2004;116(7A)
  13. Beale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Disease. 2005;7;398-402
  14. Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. MMWR. 1998;47(RR-3):1-30.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Hemochromatosis and hemosiderosis are contraindications to iron therapy.
WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
PRECAUTIONS Folic acid when administered as a single agent in doses above 0.1mg daily may obscure pernicious anemia in that hematological remission can occur while neurological manifestations remain progressive.  While prescribing this nutritional supplement for pregnant women, nursing mothers, or for women prior to conception, their medical condition and other drugs, herbs, and/or supplements consumption should be considered.
ADVERSE REACTIONS Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
See full prescribing information